Bavarian Nordic will cease work on an experimental cancer vaccine in early-stage testing and no longer invest in oncology, announcing Wednesday plans to instead prioritize its infectious disease ...
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS ® (MVA-BN) for active ...
Janssen has signed a new deal with Bavarian Nordic worth up to $836 million to develop target vaccines for hepatitis B and HIV. The projects will combine Bavarian Nordic’s MVA-BN technology with ...
A recommendation to expand the number of Americans encouraged to get an mpox vaccine has not yet been accepted by the CDC's ...
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...
Bavarian Nordic reported record financial results in 2023, earning a preliminary revenue of DKr7.06bn ($1bn) compared to DKr3 ...
(Reuters) -Denmark-based Bavarian Nordic said on Saturday it was ending its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of ...
A global shortage in the supply of a vaccine being used to protect against severe illness for monkeypox has spurred the U.S. to negotiate new terms with the sole manufacturer, Bavarian Nordic.
In February, Bavarian Nordic announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment for the upcoming ...
COPENHAGEN, Denmark, March 13, 2024 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS ® (MVA-BN) for active ...
COPENHAGEN, Denmark, March 6, 2024 - Bavarian Nordic A/S. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: "Delivering our best-ever financial results in 2023, we are now ...
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS ® (MVA-BN) for active ...